Latest Breaking News On - Investor relationse mail - Page 3 : comparemela.com

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Baden wübergNew yorkUnited statesSan diegoContactjessica yinglingMary beth sandinWolfgang fischerAffimed luminAlexander fudukidisdirectorArtiva alloArtiva biotherapeuticsContactnicholas veomettPhd little dog communications incUniversity of texas md anderson cancer centerGc cell corporationChief operating officer

Affimed to Present at the H C Wainwright Annual Global Investment Conference

Affimed to Present at the H C Wainwright Annual Global Investment Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Baden wübergNew yorkUnited statesContactalexander fudukidisdirectorAffimedn vaffimedAdi hoessAlex fudukidisChief executive officerAnnual global investment conferenceDaylight timeInvestor contactalexander fudukidisdirectorInvestor relationse mail

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Results from the ORION-8 open-label extension trial show twice-yearly Leqvio, in addition to statin therapy, provides consistent low-density lipo.

United statesSouth koreaNoord hollandDavid soergelNovartis leqvioSloan simpsonMichael meo marlena abdinoorColl cardiolJulie masowLos angelesNorman leporMetabolic drug developmentExchange commissionPublic healthCongress onNovartis pharmaceuticals corporation

IDEX Biometrics announces intention to voluntary delist of American Depositary Shares from The Nasdaq Capital Market - IDEX Biometrics (NASDAQ:IDBA)

Oslo, Norway, July 21, 2023 - IDEX Biometrics ASA (NASDAQ:IDBA) ("IDEX" or the "Company"), a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control and

New yorkUnited statesVince grazianiSecurities exchangeAdss for the companyReceipts divisionNasdaq stock market of the companyExchange commissionCompany adssNasdaq stock marketAmerican depositary sharesOslo borsNasdaq capital marketChief executive officerSecurities exchange actExchange act

IDEX Biometrics announces intention to voluntary delist of American Depositary Shares from The Nasdaq Capital Market

Oslo, Norway, July 21, 2023 - IDEX Biometrics ASA , a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control and digital identity, today.

New yorkUnited statesVince grazianiAdss for the companyNasdaq stock market of the companySecurities exchangeExchange commissionCompany adssReceipts divisionNasdaq stock marketAmerican depositary sharesOslo borsNasdaq capital marketChief executive officerSecurities exchange actExchange act